Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teenage Wasteland: Paying for New Drugs and Other "Adolescent" Technologies

This article was originally published in RPM Report

Executive Summary

The debate over comparative effectiveness research has focused heavily on standards of evidence to judge the relative value of different therapies and standards for when and how conclusions should drive coverage policy. Less attention has been paid to a more fundamental question: when should the value determination be made. CMS’ top coverage official has an idea that would radically change that process.

You may also be interested in...

CMS Takes A Look At Alzheimer’s With Lilly's Amyvid In Mind

The Alzheimer’s drug Amyvid received FDA approval for a narrower indication than the sponsors originally wanted. The limited indication got the imaging agent to market, but now Amyvid faces another challenge on the reimbursement front. 

Carving-In Innovation: Payment Reform and Biopharma

When it comes to health care reform, Democrats and Republicans don’t appear to agree on very much. But during a BIO annual meeting session, three key policymakers representing both sides of the aisle in the Senate and the Obama Administration did agree on one thing: it is time for industry to stop asking to be “carved out” of new payment systems, and to start proving the value of its products.

Accelerated Withdrawal in Action: The Avastin Hearing Process

The June hearing on the status of Genentech’s metastatic breast cancer indication for Avastin will focus on a long list of substantive disagreements about the data. But any sponsor interested in the future of the accelerated approval process should study the back-and-forth in the hearing process itself.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts